Robert Litman
Founder and Medical Director, CBH Health
CenExel

Robert E. Litman, M.D., is the Medical Director and Principal Investigator for all clinical trials at CBH Health. He developed his interest in the treatment of schizophrenia at Massachusetts General Hospital, where he completed his residency in psychiatry. Shortly thereafter, he joined the Experimental Therapeutics Branch, National Institute of Mental Health, NIH, as a Senior Staff Fellow. Remaining at NIH until 1995, he continued to pursue his interest in schizophrenia, including investigating the effects of atypical neuroleptics biological and genetic markers in schizophrenia, as well as the development of better combination therapies for schizophrenia using the alpha-2 antagonist idazoxan. After leaving the NIH, he formed his own clinical trials research organization, first in conjunction with area hospitals, and then as a free-standing inpatient and outpatient clinical research organization now known as CBH Health. Since then he has conducted over 300 Phase I-IV clinical trials and has participated in many of the important advances in pharmacotherapy of schizophrenia and other brain disorders.

Dr. Litman has an extensive background in psychopharmacology, the evaluation and treatment of schizophrenia, bipolar, major depression, anxiety, and Alzheimer’s disease. He serves as a consultant in psychopharmacology to many area hospitals and group practices, has over 30 academic publications, and frequently speaks about new advances in the field of psychopharmacology and on the current issues regarding drug development for psychiatric illness. He is currently an Associate Professor of Psychiatry at Georgetown University Medical School (where he teaches and trains psychiatry residents), a Fellow and Diplomate of the American Board of Psychiatry and Neurology, and Diplomate, Added Qualifications in Geriatric Psychiatry.